# To Evaluate the Efficacy and Safety of Abaloparatide Injection (QLG2128) in the Treatment of Postmenopausal Women With Osteoporosis and at High Risk of Fracture

> **NCT06898060** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 282 (estimated)

## Conditions studied

- Postmenopausal Women With Osteoporosis

## Interventions

- **DRUG:** QLG2128
- **DRUG:** Teriparatide Injection

## Key facts

- **NCT ID:** NCT06898060
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-06
- **Primary completion:** 2027-05
- **Final completion:** 2027-05
- **Target enrollment:** 282 (ESTIMATED)
- **Last updated:** 2025-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06898060

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06898060, "To Evaluate the Efficacy and Safety of Abaloparatide Injection (QLG2128) in the Treatment of Postmenopausal Women With Osteoporosis and at High Risk of Fracture". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06898060. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*